<DOC>
	<DOCNO>NCT00055536</DOCNO>
	<brief_summary>The purpose study determine safety , tolerability , efficacy natalizumab individual diagnose active Crohn 's Disease remission ( CDAI great than/equal 150 ) currently take Remicade . It think natalizumab may stop movement certain cell , know white blood cell , bowel tissue . These cell think cause damage bowel lead symptom Crohn 's disease . Patients complete study may eligible long-term natalizumab therapy via extension protocol ELN100226-351 .</brief_summary>
	<brief_title>Safety Efficacy Natalizumab Combination With Remicade Treatment Crohn 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Natalizumab</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Male female patient least 18 year age least sixmonth history Crohn 's disease currently receive Remicade remission ( CDAI great than/equal 150 ) Women must breastfeed pregnant , must become pregnant study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
</DOC>